Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (PHERGain)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03161353
Recruitment Status : Active, not recruiting
First Posted : May 19, 2017
Last Update Posted : June 13, 2022
Information provided by (Responsible Party):